Understand the source comparison
DSIP vs Melatonin Which Better Comparison: Research Applications and Use Cases
Primary Mechanism MT1/MT2 receptor agonist. Circadian phase signal Hypothalamic delta-wave modulation. Mechanism partially unknown Melatonin shifts timing; DSIP may enhance depth Onset Time 20–40 minutes oral Effects develop over days, not hours Melatonin for
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Primary Mechanism
- MT1/MT2 receptor agonist. Circadian phase signal
- Hypothalamic delta-wave modulation. Mechanism partially unknown
- Melatonin shifts timing; DSIP may enhance depth
- Onset Time
- 20–40 minutes oral
- Effects develop over days, not hours
- Melatonin for acute use; DSIP for multi-day cycles
- Half-Life
- 20–50 minutes
- Unknown (effects persist 48–72 hours post-dose in limited trials)
- Melatonin clears quickly; DSIP shows prolonged influence
- Human Trial Quality
- Meta-analyses available, 1,600+ participants across RCTs
- Fewer than 12 published trials, small samples, limited replication
- Melatonin has established evidence base; DSIP does not
- Typical Research Dose
- 0.3mg–10mg oral
- 25–50 nanomoles IV (oral bioavailability uncertain)
- Dosing routes differ fundamentally
- Regulatory Status
- OTC supplement (U.S.), prescription (EU, Australia)
- Research peptide. Not approved for therapeutic use anywhere
- Melatonin widely accessible; DSIP research-only